Literature DB >> 33277810

Therapy for advanced cholangiocarcinoma: Current knowledge and future potential.

Mingxun Wang1, Ziyan Chen1, Pengyi Guo2, Yi Wang3, Gang Chen1.   

Abstract

Cholangiocarcinoma (CCA) is a biliary epithelial tumour that can emerge at any point in the biliary tree. It is commonly classified based on its anatomical site of development into intrahepatic cholangiocarcinoma (ICC), perihilar cholangiocarcinoma (PCC) and distal cholangiocarcinoma (DCC), each of which is associated with varying patient demographics, molecular characteristics and treatment options. CCA patients have poor overall prognoses and 5-year survival rates. Additionally, CCA is often diagnosed at an advanced stage, with surgical treatment restricted to early-stage disease. Owing to an increase in the incidence of ICC, that of CCA is also on the rise, with a corresponding increase in the associated mortality, particularly in South America and Asia. Therefore, the development of an effective treatment is crucial to improve the survival of CCA patients. We aimed to systematically review the current understanding of advanced CCA treatment and discuss potential effective strategies.
© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

Entities:  

Keywords:  advanced tumour; cholangiocarcinoma; combination therapy; tumour therapy

Mesh:

Substances:

Year:  2020        PMID: 33277810      PMCID: PMC7812297          DOI: 10.1111/jcmm.16151

Source DB:  PubMed          Journal:  J Cell Mol Med        ISSN: 1582-1838            Impact factor:   5.295


  109 in total

1.  Genomic spectra of biliary tract cancer.

Authors:  Hiromi Nakamura; Yasuhito Arai; Yasushi Totoki; Tomoki Shirota; Asmaa Elzawahry; Mamoru Kato; Natsuko Hama; Fumie Hosoda; Tomoko Urushidate; Shoko Ohashi; Nobuyoshi Hiraoka; Hidenori Ojima; Kazuaki Shimada; Takuji Okusaka; Tomoo Kosuge; Shinichi Miyagawa; Tatsuhiro Shibata
Journal:  Nat Genet       Date:  2015-08-10       Impact factor: 38.330

Review 2.  Dendritic cells in cancer immunology and immunotherapy.

Authors:  Stefanie K Wculek; Francisco J Cueto; Adriana M Mujal; Ignacio Melero; Matthew F Krummel; David Sancho
Journal:  Nat Rev Immunol       Date:  2019-08-29       Impact factor: 53.106

3.  Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target.

Authors:  Anna Saborowski; Michael Saborowski; Monika A Davare; Brian J Druker; David S Klimstra; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-23       Impact factor: 11.205

Review 4.  Fibroblast growth factor signalling: from development to cancer.

Authors:  Nicholas Turner; Richard Grose
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

5.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

6.  Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

Authors:  Ghassan K Abou-Alfa; Teresa Macarulla; Milind M Javle; Robin K Kelley; Sam J Lubner; Jorge Adeva; James M Cleary; Daniel V Catenacci; Mitesh J Borad; John Bridgewater; William P Harris; Adrian G Murphy; Do-Youn Oh; Jonathan Whisenant; Maeve A Lowery; Lipika Goyal; Rachna T Shroff; Anthony B El-Khoueiry; Bin Fan; Bin Wu; Christina X Chamberlain; Liewen Jiang; Camelia Gliser; Shuchi S Pandya; Juan W Valle; Andrew X Zhu
Journal:  Lancet Oncol       Date:  2020-05-13       Impact factor: 41.316

7.  Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.

Authors:  Darrell R Borger; Kenneth K Tanabe; Kenneth C Fan; Hector U Lopez; Valeria R Fantin; Kimberly S Straley; David P Schenkein; Aram F Hezel; Marek Ancukiewicz; Hannah M Liebman; Eunice L Kwak; Jeffrey W Clark; David P Ryan; Vikram Deshpande; Dora Dias-Santagata; Leif W Ellisen; Andrew X Zhu; A John Iafrate
Journal:  Oncologist       Date:  2011-12-16       Impact factor: 5.837

8.  A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin.

Authors:  Yi Zheng; Xiaoxuan Tu; Peng Zhao; Weiqin Jiang; Lulu Liu; Zhou Tong; Hangyu Zhang; Cong Yan; Weijia Fang; Weilin Wang
Journal:  Br J Cancer       Date:  2018-06-29       Impact factor: 7.640

9.  The 2019 WHO classification of tumours of the digestive system.

Authors:  Iris D Nagtegaal; Robert D Odze; David Klimstra; Valerie Paradis; Massimo Rugge; Peter Schirmacher; Kay M Washington; Fatima Carneiro; Ian A Cree
Journal:  Histopathology       Date:  2019-11-13       Impact factor: 5.087

10.  Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers.

Authors:  Waraporn Chan-On; Maarja-Liisa Nairismägi; Choon Kiat Ong; Weng Khong Lim; Simona Dima; Chawalit Pairojkul; Kiat Hon Lim; John R McPherson; Ioana Cutcutache; Hong Lee Heng; London Ooi; Alexander Chung; Pierce Chow; Peng Chung Cheow; Ser Yee Lee; Su Pin Choo; Iain Bee Huat Tan; Dan Duda; Anca Nastase; Swe Swe Myint; Bernice Huimin Wong; Anna Gan; Vikneswari Rajasegaran; Cedric Chuan Young Ng; Sanjanaa Nagarajan; Apinya Jusakul; Shenli Zhang; Priya Vohra; Willie Yu; DaChuan Huang; Paiboon Sithithaworn; Puangrat Yongvanit; Sopit Wongkham; Narong Khuntikeo; Vajaraphongsa Bhudhisawasdi; Irinel Popescu; Steven G Rozen; Patrick Tan; Bin Tean Teh
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 41.307

View more
  5 in total

Review 1.  An Insight into Cholangiocarcinoma and Recent Advances in its Treatment.

Authors:  Rakesh Sahu; Praveen Sharma; Ajay Kumar
Journal:  J Gastrointest Cancer       Date:  2022-01-13

2.  Paracrine Interaction of Cholangiocellular Carcinoma with Cancer-Associated Fibroblasts and Schwann Cells Impact Cell Migration.

Authors:  Jan-Paul Gundlach; Jannik Kerber; Alexander Hendricks; Alexander Bernsmeier; Christine Halske; Christian Röder; Thomas Becker; Christoph Röcken; Felix Braun; Susanne Sebens; Nils Heits
Journal:  J Clin Med       Date:  2022-05-15       Impact factor: 4.964

3.  Comparison of Four Lymph Node Stage Methods for Predicting the Prognosis of Distal Cholangiocarcinoma Patients After Surgery.

Authors:  Xiuyi Huang; Xiaoya Niu; Zhen You; Youlin Long; Fan Luo; Hui Ye
Journal:  Front Oncol       Date:  2021-12-03       Impact factor: 6.244

Review 4.  Bicaudal-C Post-transcriptional regulator of cell fates and functions.

Authors:  Megan E Dowdle; Charlotte R Kanzler; Cole R K Harder; Samuel Moffet; Maya N Walker; Michael D Sheets
Journal:  Front Cell Dev Biol       Date:  2022-09-07

5.  Therapy for advanced cholangiocarcinoma: Current knowledge and future potential.

Authors:  Mingxun Wang; Ziyan Chen; Pengyi Guo; Yi Wang; Gang Chen
Journal:  J Cell Mol Med       Date:  2020-12-04       Impact factor: 5.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.